Boston Scientific Corporation (BSX)
Market Cap | 132.90B |
Revenue (ttm) | 15.91B |
Net Income (ttm) | 1.79B |
Shares Out | 1.47B |
EPS (ttm) | 1.21 |
PE Ratio | 74.59 |
Forward PE | 33.48 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,527,447 |
Open | 90.81 |
Previous Close | 90.33 |
Day's Range | 89.47 - 90.81 |
52-Week Range | 53.93 - 91.08 |
Beta | 0.80 |
Analysts | Strong Buy |
Price Target | 93.73 (+3.95%) |
Earnings Date | Oct 23, 2024 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, c... [Read more]
Financial Performance
In 2023, Boston Scientific's revenue was $14.24 billion, an increase of 12.29% compared to the previous year's $12.68 billion. Earnings were $1.57 billion, an increase of 144.55%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is $93.73, which is an increase of 3.95% from the latest price.
News
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
On Saturday, Boston Scientific Corporation BSX unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.
Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO , ...
Boston Scientific Corporation (BSX) UBS Global Healthcare Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-An...
Boston Scientific Closes Acquisition of Axonics, Inc.
MARLBOROUGH, Mass. , Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company ...
Kidney Stone Management Market Forecast Report, 2024-2032 - Cook Group, Richard Wolf, Boston Scientific, and Dornier MedTech Actively Engaged in M&As to Increase Share
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Kidney Stone Management Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global market size for kidn...
Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference
MARLBOROUGH, Mass. , Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024.
Boston Scientific Announces Agreement to Acquire Cortex, Inc.
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass. , Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporat...
Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Business Update Earnings Conference Call October 30, 2024 4:00 PM ET Company Participants Jonathan Monson - Senior Vice President of Investor Relations Joseph...
Why The Fundamentals Make Me Bullish On Boston Scientific
Medical devices maker Boston Scientific should continue to grow profitably through the next several years. Backing that bullishness is its history, good margins, pipeline, capital allocation, and more...
Why is Boston Scientific Stock Trading Lower On Wednesday?
On Wednesday, Boston Scientific Corporation BSX released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe, symptomatic aortic s...
ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024
MARLBOROUGH, Mass. and WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which...
Boston Scientific Profit Falls Even as Demand for Its Heart Products Surges
Boston Scientific (BSX) shares fell Wednesday when the medical equipment manufacturer's third-quarter profit fell and its GAAP earnings per share (EPS) came in short of its guidance.
Boston Scientific Corporation (BSX) Q3 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q3 2024 Earnings Conference Call October 23, 2024 8:00 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Michael Mahoney ...
Boston Scientific's stock climbs on Q3 sales and earnings beat
Medical-products company Boston Scientific reported third-quarter results before market open.
Boston Scientific lifts annual profit forecast on strong demand for heart devices
Boston Scientific raised its annual profit forecast and exceeded Wall Street's estimates for third-quarter profit on Wednesday, driven by robust demand for its heart devices, sending its shares higher...
Boston Scientific Announces Results for Third Quarter 2024
MARLBOROUGH, Mass. , Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported ...
Boston Scientific Q3 Earnings Preview
Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass. , Oct. 18, 2024 /PRNewswire/ -...
This Boston Scientific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Transverse Medical Appoints Former Boston Scientific EVP and Global Chief Medical Officer, Professor Ian T. Meredith, to Board of Directors
DENVER--(BUSINESS WIRE)-- #Cerebralembolicprotection--Transverse Medical, Inc., developer of the POINT-GUARD™ Cerebral Embolic Protection medical device, is pleased to announce the appointment of Ian ...
Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results
-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass. , Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call di...
Boston Scientific Receives Japanese Regulatory Approval for the FARAPULSE™ Pulsed Field Ablation System
MARLBOROUGH, Mass. , Sept. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the FARAP...
Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
MARLBOROUGH, Mass. , Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device c...
Boston Scientific Receives FDA Approval for Expanded Indication of INGEVITY™+ Pacing Leads to Include Conduction System Pacing of the Left Bundle Branch Area
MARLBOROUGH, Mass. , Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the indication for current-generat...
Pick Boston Scientific Stock After 130% Gains?
Boston Scientific (NYSE: BSX) has more than doubled in value since early January 2021 – jumping from levels of $36 then to around $82 now – vs. an increase of about 45% for the S&P 500 over this perio...